David Habiger Purchases 1,042 Shares of Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation (NYSE:BSX) Director David Habiger acquired 1,042 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was acquired at an average price of $48.07 per share, for a total transaction of $50,088.94. Following the completion of the purchase, the director owned 14,920 shares of the company’s stock, valued at $717,204.40. This trade represents a 7.51% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Boston Scientific Stock Performance

Shares of NYSE:BSX traded down $1.36 on Wednesday, reaching $47.73. The company’s stock had a trading volume of 16,449,695 shares, compared to its average volume of 18,405,885. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The stock has a market capitalization of $70.94 billion, a P/E ratio of 19.32, a PEG ratio of 1.06 and a beta of 0.56. The stock’s 50-day moving average is $45.78 and its two-hundred day moving average is $61.39. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the company posted $0.75 earnings per share. The business’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific declared that its board has authorized a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter valued at approximately $26,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific in the 4th quarter worth approximately $26,000. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of Boston Scientific in the 1st quarter worth approximately $28,000. Finally, Sfam LLC purchased a new position in Boston Scientific in the 4th quarter valued at approximately $29,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Robert W. Baird set a $56.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Evercore set a $65.00 target price on Boston Scientific in a research report on Monday, July 6th. Bank of America cut their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Canaccord Genuity Group decreased their price target on Boston Scientific from $70.00 to $66.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.